XARELTO: Uses, Forms and Safety Reference

XARELTO is a rivaroxaban anticoagulant supplied as tablets and a prepared oral suspension. Its several clot-related indications have different schedules and food requirements, so a strength alone is an incomplete description of the prescription.

The approved uses and formulations described here follow US prescribing information. They may differ in other countries.

Medicine detail Details
Active ingredient(s) rivaroxaban
Medicine class Direct factor Xa inhibitor anticoagulant
Forms and strengths Oral tablets: 2.5, 10, 15 and 20 mg; granules for oral suspension providing 1 mg/mL after pharmacy reconstitution

Several indications with different qualifications

US uses include adult nonvalvular atrial-fibrillation stroke prevention, DVT and pulmonary-embolism treatment and recurrence reduction, and specified surgical or medically ill-patient VTE prevention. Certain coronary and peripheral artery disease uses require aspirin. Pediatric indications include qualified VTE treatment after initial anticoagulation and thromboprophylaxis after the Fontan procedure from age 2.

Source: [1]

Strength and food instructions must match

Tablets contain 2.5, 10, 15 or 20 mg. The 15 and 20 mg tablets require food under the labeled adult instructions; other regimens have different qualifications. The oral suspension is prepared by the pharmacy to 1 mg/mL and has specific administration instructions. Do not apply adult tablet directions to a child's suspension.

Source: [1]

Serious bleeding and interaction risks

Rivaroxaban can cause serious or fatal bleeding and is contraindicated with active pathological bleeding. Seek urgent care for suspected major blood loss or significant injury. Other anticoagulants, NSAIDs, antiplatelets and strong combined P-gp/CYP3A inhibitors or inducers need review. Kidney and liver impairment can limit use or alter prescribing.

Source: [1]

Interruption and spinal-procedure boxed warnings

Stopping prematurely raises the risk of thrombotic events. Spinal or epidural bleeding around neuraxial procedures can cause lasting paralysis. Tell clinicians and dentists about rivaroxaban before procedures. The treating team should plan interruption and resumption; this reference does not give a self-directed stop or restart interval.

Source: [1]

Different phases are not duplicate prescriptions

Some treatment courses change strength or frequency after an initial phase. That transition needs clear written directions to avoid overlap or a gap. Pediatric administration is weight-based and has feeding and preparation qualifications. The presence of a once-daily regimen for one indication does not make every XARELTO course once daily.

The ELIQUIS and XARELTO comparison brings the two product identities and selected label facts together for further reading.

Source: [1]

Questions and answers

Do all XARELTO tablet strengths have identical food instructions?

No. Adult 15 and 20 mg tablets require food; follow the specific product and indication instructions.

Can a child's suspension follow an adult tablet schedule?

No. Pediatric treatment has weight-based dosing, feeding and administration requirements.

Why might a prescription change strength during clot treatment?

The label has different initial and continuing phases for some indications. The prescriber must explain the exact transition.

Related reading

Sources

  1. XARELTO: official US prescribing information

Sources checked 27 October 2026. This information does not replace advice from your healthcare professional. For complete warnings and instructions, read the product information and consult the prescribing team.

Reviewed by: Mattias Hagman, PhD

About the reviewer:
Dr Mattias Hagman (PhD, University of Sydney) has an academic background and experience working with healthcare-related content and regulated industries. He has lecturing experience at international universities, including Stockholm University and the University of Malta.

Last reviewed: October 2026